All In Biotech

Drug Trial Radar · NCT05291325

Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy

Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy: a Multicenter, Randomized, Controlled Clinical Study

Last checked: Nov 19, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,607 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,607

Actual

Start

May 25, 2022

Primary completion

Aug 30, 2023

Study completion Apr 28, 2024

Sponsor

Lead sponsor
Changhai HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanxi Provincial People's Hospital; 900th Hospital of PLA Joint Logistic Support Force; Ruijin Hospital; The First Affiliated Hospital of Nanchang University; Qilu Hospital of Shandong University; The Affiliated Hospital of Qingdao University; The Third Affiliated Hospital of Wenzhou Medical University; Affiliated Yueqing Hospital of Wenzhou Medical University; The First Affiliated Hospital of Soochow University; Seventh Medical Center of PLA Army General Hospital; The First Hospital of Jilin University; The Second Hospital of Hebei Medical University; The Affiliated Hospital of Inner Mongolia Medical University; The Second Affiliated Hospital of Dalian Medical University; General Hospital of Ningxia Medical University; Affiliated Hospital of Qinghai University; The First People's Hospital of Yunnan; Second Xiangya Hospital of Central South University; Shanghai Zhongshan Hospital; Daping Hospital of Army Medical University; Zunyi Medical College; Huizhou Municipal Central Hospital; Affiliated Hospital of Southwest Medical University; The First Affiliated Hospital of Shihezi University; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; The Second Affiliated Hospital of Air Force Military Medical University
First posted
Mar 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The clinical purpose of this study was to investigate whether the adjuvant application of linaclotide in bowel preparation for colonoscopy could improve the quality of bowel preparation or reduce the dosage of laxatives.

Conditions

  • Bowel Preparation for Colonoscopy

Interventions

  • 3L PEG + LinaclotideDrug

    Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.

  • 3L PEGDrug

    Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.

  • 2L PEG + LinaclotideDrug

    Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bowel preparation adequate rateTime frame: within 10 minute after viewing colonoscopy video.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Changhai Hospital, Naval Medical University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.